Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Acromegaly

Acromegaly

0 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Acromegaly

35 trials tracked for Acromegaly: 16 in phase 3 or 4 and 5 with published results. The most-cited published study has 85 citations.

35Trials tracked
16Phase 3 & 4
0Recruiting
5With published results
Phase distribution
Phase 4 6 Phase 3 10 Phase 2 11 Other / NA 8
  1. Phase 3 Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients Completed · 85 cited
  2. Phase 4 Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly Completed · 80 cited
  3. Phase 3 Comparison of Oral Octreotide Capsules to Injectable Somatostatin Analogs in Acromegaly Completed · 55 cited
  4. Phase 3 Pasireotide in Patients With Acromegaly Inadequately Controlled With First Generation Somatostatin Analogues Completed · 40 cited
  5. Phase 3 Efficacy and Safety of Lanreotide Autogel® 60, 90 or 120 mg With Lanreotide 40 mg Prolonged Release (PR) in Acromegaly Completed · 3 cited
  6. Phase 4 Ultrasound Guided Octreotide LAR Injection in Acromegaly Completed
Show 29 more trials
  1. Phase 4 Effects of Sandostatin LAR® in Acromegaly Completed
  2. Phase 4 Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies Completed
  3. Phase 4 Study to Assess the Efficacy of an Extended Injection Interval Schedule of Lanreotide Autogel in Acromegalic Subjects Completed
  4. Phase 4 Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic Patients Completed
  5. Phase 3 Efficacy and Safety of Octreotide (MYCAPSSA™ [Formerly Octreolin™]) for Acromegaly Completed
  6. Phase 3 Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel Completed
  7. Phase 3 Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly Completed
  8. Phase 3 Efficacy/Safety of Octreotide Acetate in Patients With Uncontrolled Acromegaly Completed
  9. Phase 3 Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly Completed
  10. Phase 3 Lanreotide as Primary Treatment for Acromegalic Patients With Pituitary Gland Macroadenoma Completed
  11. Phase 2 Safety, Tolerability, and Efficacy of IONIS-GHR-LRx in Participants With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands Completed
  12. Phase 2 Efficacy and Safety of Pasireotide LAR (Long-acting Release) in Japanese Patients With Acromegaly or Pituitary Gigantism Completed
  13. Phase 2 Single Dose Pharmacology Study of DG3173 and Octreotide in Acromegalic Patients. Completed
  14. Phase 2 The Effect of Subcutaneous Infusions of 3 Doses of DG3173 on Growth Hormone Levels in Untreated Acromegalics Completed
  15. Phase 2 A Study to Assess the Safety, Tolerability, and Efficacy of IONIS-GHR-LRx Administered in Patients With Acromegaly Completed
  16. Phase 2 Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs) Completed
  17. Phase 2 An Extension Study to Assess the Long-Term Safety and Efficacy of Pasireotide in Participants With Acromegaly Completed
  18. Phase 2 A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Evolve) Completed
  19. Phase 2 Study to Determine the Maximum Tolerated Dose, Safety and Tolerability of a Single Dose of Lanreotide Prolonged Release Formulation (PRF) in Subjects With Acromegaly Completed
  20. Phase 2 An Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Edge) Completed
  21. Phase 2 Clomiphene Citrate for Treatment of Acromegaly Completed
  22. N/A Acromegaly Treatment Quality of Life Study Completed
  23. N/A Tissue Biomarker for Pegvisomant Action Completed
  24. N/A Effects of Growth Hormone Administration on Cardiovascular Risk in Cured Acromegalics With Growth Hormone Deficiency Completed
  25. N/A Growth Hormone Feedback to Insulin-like Growth Factor-I (IGF-1) and Oral Glucose Tolerance Test (OGTT) Completed
  26. N/A Non Interventional Study For Patients Treated With Somavert® Completed
  27. N/A Ectopic Lipid Deposition and Insulin Resistance in After Treatment of Acromegaly Completed
  28. N/A Long Term Use of Somavert (Pegvisomant) For A Regulatory Post Marketing Commitment Plan Completed
  29. N/A Programme of Acromegaly Screening in Patients With Associated Somatic Disorders Completed

Showing the 35 most-cited and recently-updated of 35 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
No published articles yet for this condition. Check back soon.